Avant Technologies Inc (AVAI)

$0.39 0.00 (-0.71%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 102,800
Avg Vol 119,666
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 34%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Avant Technologies Inc. acquires, creates, and develops artificial intelligence (AI) technologies. It also offers information technology (IT) consulting services. The company provides full-stack software development, database management, data integration, project management and cloud services resources. Further, it offers Avant! AI, a platform that has shown impressive results related to the technology's usage, access, and performance; and InstantFAME. The company was formerly known as Trend Inn...

Industry: Software - Application
Sector: Technology
Address:
Sv. Stepono g. 27D-2, LT-01315, Vilnius, Lithuania
resx18
resx18 Aug. 22 at 2:02 PM
$AVAI looking good here!
0 · Reply
resx18
resx18 Aug. 22 at 12:12 PM
$AVAI https://www.reddit.com/r/pennystocks/comments/1mx3l6l/avant_technologies_otcqb_avai_strategic/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button
0 · Reply
MatrixStocks
MatrixStocks Aug. 21 at 1:02 PM
$AVAI Let's Have a Day Here !
0 · Reply
mfay797
mfay797 Aug. 21 at 11:41 AM
$AVAI AI in healthcare advancements is gaining attention, not long now !
0 · Reply
MatrixStocks
MatrixStocks Aug. 20 at 3:14 PM
$AVAI Avant Technologies (OTCQB: $AVAI) News Update ⚡️ Avant Technologies (OTCQB: $AVAI) and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial ⚡️ The planned clinical study, which will be performed in 8-10 clinical sites around the U.S., will prioritize the recruitment of approximately 1,000 multiethnic patients, with a focus on individuals living with diabetes. 💥 We are getting closer to initiating a clinical study that will significantly contribute to obtaining FDA 510(k) approval.
0 · Reply
AnitaDump
AnitaDump Aug. 20 at 2:54 PM
$AVAI
0 · Reply
resx18
resx18 Aug. 20 at 2:37 PM
$AVAI
0 · Reply
mfay797
mfay797 Aug. 20 at 12:50 PM
$AVAI .49+ were on our way imo
0 · Reply
MatrixStocks
MatrixStocks Aug. 20 at 12:36 PM
$AVAI Let's get over .50 today!
0 · Reply
mfay797
mfay797 Aug. 20 at 12:27 AM
$AVAI
0 · Reply
Latest News on AVAI
No data available.
resx18
resx18 Aug. 22 at 2:02 PM
$AVAI looking good here!
0 · Reply
resx18
resx18 Aug. 22 at 12:12 PM
$AVAI https://www.reddit.com/r/pennystocks/comments/1mx3l6l/avant_technologies_otcqb_avai_strategic/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button
0 · Reply
MatrixStocks
MatrixStocks Aug. 21 at 1:02 PM
$AVAI Let's Have a Day Here !
0 · Reply
mfay797
mfay797 Aug. 21 at 11:41 AM
$AVAI AI in healthcare advancements is gaining attention, not long now !
0 · Reply
MatrixStocks
MatrixStocks Aug. 20 at 3:14 PM
$AVAI Avant Technologies (OTCQB: $AVAI) News Update ⚡️ Avant Technologies (OTCQB: $AVAI) and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial ⚡️ The planned clinical study, which will be performed in 8-10 clinical sites around the U.S., will prioritize the recruitment of approximately 1,000 multiethnic patients, with a focus on individuals living with diabetes. 💥 We are getting closer to initiating a clinical study that will significantly contribute to obtaining FDA 510(k) approval.
0 · Reply
AnitaDump
AnitaDump Aug. 20 at 2:54 PM
$AVAI
0 · Reply
resx18
resx18 Aug. 20 at 2:37 PM
$AVAI
0 · Reply
mfay797
mfay797 Aug. 20 at 12:50 PM
$AVAI .49+ were on our way imo
0 · Reply
MatrixStocks
MatrixStocks Aug. 20 at 12:36 PM
$AVAI Let's get over .50 today!
0 · Reply
mfay797
mfay797 Aug. 20 at 12:27 AM
$AVAI
0 · Reply
AnitaDump
AnitaDump Aug. 19 at 1:49 PM
$AVAI
0 · Reply
AnitaDump
AnitaDump Aug. 19 at 1:19 PM
$AVAI
0 · Reply
mfay797
mfay797 Aug. 19 at 1:17 PM
$AVAI lets have a day!
0 · Reply
resx18
resx18 Aug. 18 at 6:19 PM
$AVAI adding all I can at these low prices.
0 · Reply
MatrixStocks
MatrixStocks Aug. 18 at 3:04 PM
$AVAI FDA Clinical Trial Progress Accelerates with Enhanced Recruitment: On August 12, 2025, Avant Technologies and Ainnova Tech announced a refined patient recruitment strategy for their Vision AI platform's U.S. clinical trial, targeting 1,000 multiethnic diabetic patients across 8-10 sites in community clinics.
0 · Reply
AnitaDump
AnitaDump Aug. 18 at 3:03 PM
$AVAI LETS GO !!
0 · Reply
resx18
resx18 Aug. 18 at 1:31 PM
$AVAI Avant Technologies (OTCQB: AVAI) and Ainnova Tech Bolster FDA Clinical Trial Strategy and Global Reach for Vision AI Platform FDA Clinical Trial Progress Accelerates with Enhanced Recruitment: On August 12, 2025, Avant Technologies and Ainnova Tech announced a refined patient recruitment strategy for their Vision AI platform's U.S. clinical trial, targeting 1,000 multiethnic diabetic patients across 8-10 sites in community clinics. ✅ Avant Technologies (OTCQB: $AVAI): A Rising Star in AI-Driven Healthcare Innovation Clinical Protocol Advanced Post-FDA Feedback: July 29, 2025, marked a key milestone as Ainnova revised its clinical trial protocol based on FDA input from a mid-July meeting, with resubmission imminent.
0 · Reply
resx18
resx18 Aug. 18 at 1:30 PM
$AVAI
0 · Reply
resx18
resx18 Aug. 18 at 11:29 AM
$AVAI Good article on the applications of AI in Healthcare. https://www.foreseemed.com/artificial-intelligence-in-healthcare
0 · Reply
mfay797
mfay797 Aug. 18 at 9:30 AM
$AVAI AI in healthcare is surging$
0 · Reply
LewisDaKat
LewisDaKat Aug. 13 at 12:55 AM
News Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial https://marketwirenews.com/news-releases/avant-technologies-and-ainnova-tech-announce-enhance-5674202876400104.html $AVAI
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 12 at 12:27 PM
$AVAI Avant and Ainnova have unveiled a refined patient recruitment strategy for their upcoming FDA clinical trial targeting early detection of diabetic retinopathy using the Vision AI platform. The trial is set to be conducted at 8–10 clinical sites across the U.S., with the aim to enroll around 1,000 multiethnic diabetic patients, primarily through community clinics and primary care facilities to gather real-world data . Approval not yet granted: This update refines preparation but isn’t a regulatory milestone.
0 · Reply